Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest’s Lexapro Okayed For Adolescents With Major Depressive Disorder

This article was originally published in The Pink Sheet Daily

Executive Summary

SSRI is only the second antidepressant approved for treatment in adolescents.

You may also be interested in...



Missing Clinical Trial Data: "Mixed Model" Approach Gains Ground At FDA

Clinical trial sponsors should adopt a mixed statistical model to cope with missing data rather than relying on the "last observation carried forward" model that was formerly perceived as regulators' favorite

Missing Clinical Trial Data: "Mixed Model" Approach Gains Ground At FDA

Clinical trial sponsors should adopt a mixed statistical model to cope with missing data rather than relying on the "last observation carried forward" model that was formerly perceived as regulators' favorite

Forest’s Lexapro Okayed For Adolescents With Major Depressive Disorder

SSRI is only the second antidepressant approved for treatment in adolescents.

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel